JP2023546140A5 - - Google Patents
Info
- Publication number
- JP2023546140A5 JP2023546140A5 JP2023523099A JP2023523099A JP2023546140A5 JP 2023546140 A5 JP2023546140 A5 JP 2023546140A5 JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023546140 A5 JP2023546140 A5 JP 2023546140A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutically acceptable
- acceptable derivative
- levodopa
- opicapone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2016425.7A GB202016425D0 (en) | 2020-10-16 | 2020-10-16 | Treatment regimens for parkinson's disease |
| GB2016425.7 | 2020-10-16 | ||
| PCT/PT2021/050036 WO2022081033A1 (en) | 2020-10-16 | 2021-10-14 | Opicapone and levodopa for the treatment of parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546140A JP2023546140A (ja) | 2023-11-01 |
| JP2023546140A5 true JP2023546140A5 (https=) | 2024-10-11 |
Family
ID=73598546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523099A Pending JP2023546140A (ja) | 2020-10-16 | 2021-10-14 | パーキンソン病の治療のためのオピカポン及びレボドパ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230398105A1 (https=) |
| EP (1) | EP4228618A1 (https=) |
| JP (1) | JP2023546140A (https=) |
| KR (1) | KR20230088753A (https=) |
| CN (1) | CN116490171A (https=) |
| AU (1) | AU2021360114A1 (https=) |
| GB (1) | GB202016425D0 (https=) |
| WO (1) | WO2022081033A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| EP4262798A1 (en) * | 2020-12-17 | 2023-10-25 | Bial-Portela & CA, S.A. | Treatment regimens for early idiopathic parkinson's disease |
| GB202212082D0 (en) * | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009116882A1 (en) | 2008-03-17 | 2009-09-24 | Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
| BRPI1016132B8 (pt) | 2009-04-01 | 2021-05-25 | Bial Portela & Ca Sa | composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| JP6456143B2 (ja) | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| PT3341380T (pt) * | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
| MX383906B (es) * | 2015-10-09 | 2025-03-14 | Teva Pharmaceuticals Int Gmbh | Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson |
| JP2020023540A (ja) * | 2019-10-11 | 2020-02-13 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
-
2020
- 2020-10-16 GB GBGB2016425.7A patent/GB202016425D0/en not_active Ceased
-
2021
- 2021-10-14 CN CN202180077619.0A patent/CN116490171A/zh active Pending
- 2021-10-14 JP JP2023523099A patent/JP2023546140A/ja active Pending
- 2021-10-14 KR KR1020237016045A patent/KR20230088753A/ko active Pending
- 2021-10-14 EP EP21801249.0A patent/EP4228618A1/en active Pending
- 2021-10-14 WO PCT/PT2021/050036 patent/WO2022081033A1/en not_active Ceased
- 2021-10-14 AU AU2021360114A patent/AU2021360114A1/en active Pending
- 2021-10-14 US US18/032,034 patent/US20230398105A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230355560A1 (en) | Medicaments for slowing parkinson's disease | |
| JP2572768B2 (ja) | レボドパメチルエステルを有効成分とするパ−キンソン病治療剤 | |
| JP2023546140A5 (https=) | ||
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| JP2023552700A5 (https=) | ||
| US20060173074A1 (en) | Treatment of restless legs syndrome | |
| Khan | Off spells and dyskinesias: pharmacologic management of motor complications | |
| KR20230088753A (ko) | 파킨슨병 치료를 위한 오피카폰 및 레보도파 | |
| JP2016505050A5 (https=) | ||
| Ahlskog | Cheaper, simpler, and better: tips for treating seniors with Parkinson disease | |
| JP2024527175A5 (https=) | ||
| JP2024525897A5 (https=) | ||
| Stocchi et al. | Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients | |
| Obering et al. | Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson's disease | |
| Zoe et al. | High-dose clonidine in a case of restless legs syndrome | |
| JP2021530568A5 (https=) | ||
| Isaacson et al. | Improving symptom control in early Parkinson’s disease | |
| EP2709608B1 (en) | Compositions for treating postural reflex abnormality caused by parkinson's disease | |
| Brydon et al. | An update of opicapone in Parkinson’s disease: evidence-based results of recent trials | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| Vo et al. | Guidelines for the Use of Parkinsonian Drugs (in USA) | |
| Dolhun et al. | Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
| Hardie | Problems and unanswered questions concerning levodopa treatment in Parkinson's disease | |
| Lang et al. | CQA 206-291 in Parkinson's disease: an acute single escalating dosage study |